Clinical Trial Update: A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) [Phase 2, Phase 3]

View source ↗

Summary

A study evaluating Navlimetostat (BMS-986504) with nab-paclitaxel and gemcitabine versus placebo with nab-paclitaxel and gemcitabine in untreated metastatic pan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• Navlimetostat

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING